当前位置: X-MOL 学术J. Vet. Cardiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A review of the underlying genetics and emerging therapies for canine cardiomyopathies
Journal of Veterinary Cardiology ( IF 1.2 ) Pub Date : 2021-05-21 , DOI: 10.1016/j.jvc.2021.05.003
L Shen 1 , A H Estrada 2 , K M Meurs 3 , M Sleeper 2 , C Vulpe 4 , C J Martyniuk 4 , C A Pacak 5
Affiliation  

Cardiomyopathies such as Dilated Cardiomyopathy (DCM) and Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) are common in large breed dogs and carry an overall poor prognosis. Research shows that these diseases have strong breed predilections, and selective breeding has historically been recommended to reduce the disease prevalence in affected breeds. Treatment of these diseases is typically palliative and aimed at slowing disease progression and managing clinical signs of heart failure as they develop. The discovery of specific genetic mutations underlying cardiomyopathies, such as the striatin mutation in Boxer ARVC and the pyruvate dehydrogenase kinase 4 (PDK4) and titin mutations in Doberman Pinschers, has strengthened our ability to screen and selectively breed individuals in an attempt to produce unaffected offspring. The discovery of these disease-linked mutations has also opened avenues for the development of gene therapies, including gene transfer and genome editing approaches. This review discusses the known genetics of cardiomyopathies in dogs, reviews existing gene therapy strategies and the status of their development in canines, and discusses ongoing challenges in the clinical translation of these technologies for treating heart disease. While challenges remain in utilizing these emerging technologies, the exponential growth of the gene therapy field holds great promise for future clinical applications.



中文翻译:

犬类心肌病的基础遗传学和新兴疗法综述

扩张型心肌病 (DCM) 和致心律失常性右心室心肌病 (ARVC) 等心肌病在大型犬中很常见,总体预后较差。研究表明,这些疾病具有很强的品种偏好,历史上一直建议选择育种以减少受影响品种的疾病流行。这些疾病的治疗通常是姑息性的,目的是减缓疾病进展和管理心力衰竭的临床症状。心肌病潜在特定基因突变的发现,例如拳击犬 ARVC 中的纹状蛋白突变和杜宾犬中的丙酮酸脱氢酶激酶 4 (PDK4) 和肌联蛋白突变,加强了我们筛选和选择性繁殖个体以试图产生未受影响后代的能力. 这些与疾病相关的突变的发现也为基因疗法的发展开辟了道路,包括基因转移和基因组编辑方法。这篇综述讨论了已知的犬心肌病遗传学,回顾了现有的基因治疗策略及其在犬科动物中的发展状况,并讨论了将这些技术用于治疗心脏病的临床转化所面临的持续挑战。虽然在利用这些新兴技术方面仍然存在挑战,但基因治疗领域的指数级增长为未来的临床应用带来了巨大希望。回顾了现有的基因治疗策略及其在犬科动物中的发展状况,并讨论了将这些技术用于治疗心脏病的临床转化所面临的持续挑战。虽然在利用这些新兴技术方面仍然存在挑战,但基因治疗领域的指数级增长为未来的临床应用带来了巨大希望。回顾了现有的基因治疗策略及其在犬科动物中的发展状况,并讨论了将这些技术用于治疗心脏病的临床转化所面临的持续挑战。虽然在利用这些新兴技术方面仍然存在挑战,但基因治疗领域的指数级增长为未来的临床应用带来了巨大希望。

更新日期:2021-05-22
down
wechat
bug